UEGJournal Abstracts 2021 - 56

Tuesday, October 5, 2021
Monday, October 4, 2021
Sunday, October 3, 2021
However, compared to those with no prior antibiotic use, recent 30-day
use only actually showed a lower risk of retreatment (OR: 0.87, 95% CI
0.77-0.99); while distant use only (OR 1.31, 95% CI 1.23-1.40) and use in
both periods (OR 1.30, 95% CI 1.12-1.51) were associated with higher risks
of retreatment. Specifically, recent use of cephalosporins (within 30 or 60
days) or metronidazole (within 30 days) were significantly associated with
lower risk of retreatment.
Conclusion: While prior antibiotic use generally increases the risk of treatment
failure of clarithromycin-containing triple therapy, recent use of specific
classes of antibiotics (cephalosporin and metronidazole) may actually
increase treatment success. Results from this population-based study
illustrate the dynamic temporal effects of prior antibiotic use on treatment
outcome and emergence of antibiotic resistance.
Disclosure: Nothing to disclose.
activity for UC and CD and was significantly higher compared to patients
in remission (p<0.001). Fecal-CP and Bühlmann serum-CP demonstrated
an inferior correlation to SES-CD score than CPa9-HNE (Fecal-CP: r=0.38,
p=0.031; Bühlmann serum-CP: r=0.018, p=0.89) and full mayo score for UC
(fecal-CP: r=0.42, P=0.030; Bühlmann serum-CP: r=0.14, p=0.41).
Lastly, CPa9-HNE levels in serum correlated to fecal calprotectin levels and
neutrophil count in IBD patients (Fecal Calprotectin: r=0.44, P=0.02; Neutrophil
count: r=0.38, p=0.04).
Conclusion: Serum CPa9-HNE levels were highly elevated in CD and UC
patients and separated from healthy controls with high diagnostic accuracy.
Furthermore, CPa9-HNE correlated with SES-CD score and full mayo
score indicating a strong association with disease activity.
Disclosure: J.H. Mortensen, T. Manon-Jensen, C.S. Thudium, M.A. Karsdal
and A-C. Bay-Jensen are employed at Nordic Bioscience A/S. T. ManonJensen,
M.A. Karsdal and A-C. Bay-Jensen own stocks at Nordic Bioscience.
IBD
diagnostics and biomarkers
09:00-10:00 / Hall 1
OP071
NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTIN DERIVED
FROM HUMAN NEUTROPHIL ELASTASE (CPA9-HNE) IS A NOVEL SERUM
CALPROTECTIN BIOMARKER OF INFLAMMATION AND DISEASE ACTIVITY
FOR IBD
J.H. Mortensen1, D. Sinkeviciute1
, A.-C. Bay-Jensen1
V. Domislovic2, M. Brinar2, P. Önnerfjord3
M.A. Karsdal1
, T. Manon-Jensen1
, Z. Krznaric2
,
,
1Nordic Bioscience A/S, Herlev, Denmark, 2
University Hospital
Centre Zagreb, Department of Gastroenterology and Hepatology,
Zagreb, Croatia, 3
Lund, Sweden
Lund University, Department of Clinical Sciences,
Contact E-Mail Address: jhm@nordicbio.com
Introduction: Clinical evaluation of inflammatory bowel disease (IBD)
patients using fecal calprotectin (fecal-CP) is challenging, because of
handling/processing of fecal samples, fecal consistency, day to day and
sample to sample variations. Thus, an alternative serum calprotectin assay
that provides robust evaluation of calprotectin and inflammation is
urgently needed. Calprotectin and human neutrophil elastase (HNE) are
highly expressed by neutrophil granulocytes and both released as part of
NETosis. Therefore, these are great candidates as markers of intestinal inflammation
in IBD.
Aims & Methods: We sought to develop a novel serum calprotectin ELISA,
which quantifies a specific fragment of HNE mediated degradation of calprotectin
(S100a9), referred to as CPa9-HNE, with the aim of being able to
monitor endoscopic disease activity in IBD patients. In vitro cleavage was
performed by mixing purified calprotectin, composed of both S100A9 and
S100A8 dimers, with HNE. The lysate was analyzed by Mass spectrometry
(MS), data was obtained using an Orbitrap mass spectrometer (Q-Exactive)
and a novel HNE derived calprotectin neo-epitope was identified. A neoepitope
specific monoclonal antibody was used to develop the CPa9-HNE
competitive ELISA. The CPa9-HNE ELISA was tested in serum samples
from 36 ulcerative colitis (UC) patients, 51 Crohn's disease (CD) patients
and 25 healthy subjects. For comparison, fecal-CP and Bühlmann serumCP
(MRP8/14 ELISA) were also measured.
Results: Serum CPa9-HNE levels were ~4-fold higher in CD (AUC: 0.98,
p<0.0001), UC (AUC: 0.91, p<0.0001) and IBD (AUC:0.95, p<0.0001) patients
compared to healthy subjects. The CPa9-HNE correlated well with SES-CD
score (r=0.61, p<0.0001) and the full mayo score for UC (r=0.52, p=0.0013).
High levels of CPa9-HNE was associated with moderate or severe disease
56
OP072
EARLY PREDICTORS OF SURGERY IN PATIENTS WITH ACUTE SEVERE
ULCERATIVE COLITIS: RESULTS OF AN INTERNATIONAL COHORT STUDY
M. Frasson1, T. Pinkney2
I. Rodríguez-Lago5
, J. Gisbert3
G. Fiorino9, C.J. Buskens10
G. Gallo14
, G. Pellino4
,
, O. Zmora6, K.B. Gecse7, S. Blackwell8
, M.J. Brookes11
, S. Leone12
, A. Verjee15, P. Nos Mateu16, C.H. Knowles17
Group
1
3
,
MASC (Management of Acute Severe Colitis) Collaborating Group
and ESCP (European Society of Coloproctology) Cohort Study
Research Institute La Fe & University Hospital La Fe, Surgery,
Valencia, Spain, 2
Birmingham, Birmingham, United Kingdom,
Hospital Universitario de La Princesa, Instituto de Investigación
Sanitaria Princesa (IP) and CIBERE, Digestive Services, Madrid,
Spain, 4
Università degli Studi della Campania " Luigi Vanvitelli " ,
Department of Advanced Medical and Surgical Sciences, Aversa
(CE), Italy, 5
Hospital de Galdakao, Gastroenterology, Galdakao,
Spain, 6Assaf Harofeh Medical Center Official, Tel Aviv, Israel,
7
Academic Medical Center (AMS), Departement of Gastroenterology
and Hepatology, Amsterdam, Netherlands, 8
Group, Liverpool, United Kingdom, 9
Rozzano, Italy, 10
Netherlands, 11
ACPGBI Patient Liaison
IRCCS Humanitas, IBD Center,
Wolverhampton, United Kingdom, 12
Academic Medical Center, Surgery, Amsterdam,
Wolverhampton Hospital, Gastroenterology Unit,
E.F.C.C.A. European Federation
of Crohn's and Ulcerative Colitis Associations, Palermo, Italy,
13
Azienda Sanitaria Provinciale Cosenza, Giannettasio HospitaI,
Cosenza, Italy, 14
and Surgical Sciences, Catanzaro, Italy, 15
Hospital NHS Foundation Trust, Homerton, United Kingdom,
16
University of Catanzaro, Department of Medical
Homerton University
Hospital La Fe, Valencia, Spain, 17Queen Mary University of
London School of Medicine NCBRSI, NBRC, London, United States
Contact E-Mail Address: dr.frasson.matteo@gmail.com
Introduction: Acute Severe Ulcerative Colitis (ASUC) is a serious, potentially
life-threatening condition requiring immediate hospitalization. The
standard approach after failed salvage medical management is total or
sub-total colectomy with formation of an end-ileostomy and preservation
of the rectum/recto-sigmoid. Delayed colectomy is associated with
increased risk of post-operative complications and multidisciplinary management
(medical/surgical) is critical to optimise surgical timing.
Aims & Methods:
Aims: To identify early predictors of failure to medical treatment and need
of colectomy in patients with ASUC.
UEG Journal | Abstract Book
,
, F. Pata13
,
UEGJournal Abstracts 2021

Table of Contents for the Digital Edition of UEGJournal Abstracts 2021
